Plaintiff Firms Intensify Biotech Securities Suits as Key Deadlines Near for Nektar, uniQure and REGENXBIO

Overview

• Law firms escalated investor outreach this week, with Hagens Berman updating its uniQure probe after public FDA rebukes and reminding QURE holders of an April 13 lead‑plaintiff deadline.
• Kessler Topaz filed Scocco v. uniQure in the Southern District of New York, alleging the company misrepresented FDA support for using an external control and minimized likely delays to its AMT‑130 filing plan.
• Multiple firms, including Schall, DJS, Faruqi, and Robbins, urged Nektar investors to seek lead‑plaintiff status by May 5 over claims the REZOLVE‑AA alopecia study broke enrollment rules and overstated its integrity.
• Rosen also called on REGENXBIO shareholders to join a suit alleging misleading statements about the RGX‑111 trial for Hurler syndrome, with a lead‑plaintiff deadline in mid‑April.
• None of the cases has a certified class, so investors are unrepresented unless they retain counsel, and the lead‑plaintiff selections will determine who directs the litigation.